The advantages of a gonadotropin releasing hormone agonist (leuprolide acetate) in conjunction with gonadotropins for controlled ovarian hyperstimulation in IVF and GIFT cycles

  • J. F. Kerin
Part of the Archives of Gynecology and Obstetrics book series (AGYO)


Since the incorporation of gonadotropin releasing hormone agonists (GnRHa) in controlled ovarian hyperstimulation (COH) regimes with various combinations of gonadotropins, there is evidence that specific advantages are obtained from using these agonists in invitro fertilization (IVF) and gamete intrafallopian tube transfer (GIFT) procedures. There is evidence that the increased efficiency rate in terms of pregnancy per IVF & GIFT cycle initiated, stems largely, from a reduced treatment cycle cancellation rate prior to oocyte harvest due to a relative increase in follicle stimulating hormone (FSH) to luteinizing hormone (LH) concentration and the inhibition of a preovulatory LH rise, resulting in improved follicle growth, endocrine responses and more healthy oocytes available for fertilization.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Knobil E (1980) The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 36: 53–88PubMedGoogle Scholar
  2. 2.
    Meldrum DR, Tsao Z, Monroe SE (1984) Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women. J Clin Endocrinol Metab 58: 755–757PubMedCrossRefGoogle Scholar
  3. 3.
    Serafini P, Stone B, Kerin J, Batzofin J, Quinn P, Marrs R (1988) An alternate approach to controlled ovarian hyperstimulation in “poor responders”: pretreatment with a gonadotropin-releasing hormone analog. Fertil Steril 49: 90–95PubMedGoogle Scholar
  4. 4.
    Brzyski RG, Mausher SJ, Droesch K, Simonetti S, Jones GS, Rosenwaks Z (1988) Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment. Fertil Steril 50: 917–921PubMedGoogle Scholar
  5. 5.
    Katayama KP, Roesler M, Gunnarson C, Stehlik E, Jagusch S (1988) Short-term use of gonadotropin-releasing hormone agonist (Leuprolide) for in vitro fertilization. J In Vitro Fertil Embryo Transfer 5: 332–334CrossRefGoogle Scholar
  6. 6.
    Serafini P, Batzofin J, Kerin J, Marrs R (1988) Pregnancy: a risk to initiation of leuprolide acetate during the luteal phase before controlled ovarian hyperstimulation. Fertil Steril 50: 371–372PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • J. F. Kerin
    • 1
  1. 1.Centre for Reproductive Medicine, Cedars-Sinai Medical CenterUCLA School of MedicineLos AngelesUSA

Personalised recommendations